SCHEMBL20209037

SCHEMBL20209037

Cc1c(N2CCN(C)[C@@H](C)C2)cc(C)c2c3c(c(=O)oc12)CN(C(=O)OC(C)(C)C)CC3

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MTHFD2 P13995 14/20 0.47
MTHFD1 P11586 9/20 0.47
WDR5 P61964 4/20 0.35
ESR2 Q92731 1/20 0.33
P2RX3 P56373 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20209038 0.89 MTHFD2 (0.46) MTHFD2MTHFD1ESR2P2RX3
SCHEMBL31535260 0.88 MTHFD2 (0.39) MTHFD2MTHFD1P2RX3
SCHEMBL21354119 0.88 MTHFD2 (0.51) MTHFD2MTHFD1WDR5
SCHEMBL20208868 0.86 MTHFD2 (0.60) MTHFD2MTHFD1
SCHEMBL20209301 0.80 ESR2 (0.42) MTHFD2ESR2P2RX3
SCHEMBL20208554 0.77 MTHFD2 (0.59) MTHFD2MTHFD1
SCHEMBL21417117 0.77 MTHFD2 (0.59) MTHFD2MTHFD1
SCHEMBL30038703 0.77 MTHFD2 (0.59) MTHFD2MTHFD1
SCHEMBL24439860 0.77 MTHFD2 (0.69) MTHFD2MTHFD1WDR5
SCHEMBL21354117 0.76 MTHFD2 (0.81) MTHFD2MTHFD1WDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3546463-B1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO CO LTD (JP) 2022-12-07 EP disclosed
EP-3546463-B1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO CO LTD (JP) 2022-12-07 EP disclosed
US-10774087-B2 Sulfonamide derivative having coumarin skeleton DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-09-15 US disclosed
US-10774087-B2 Sulfonamide derivative having coumarin skeleton DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-09-15 US disclosed
EP-3546463-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON Daiichi Sankyo Co., Ltd. (JP) 2019-10-02 EP disclosed
EP-3546463-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON Daiichi Sankyo Co., Ltd. (JP) 2019-10-02 EP disclosed
US-20190284198-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-09-19 US disclosed
US-20190284198-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-09-19 US disclosed
WO-2018097162-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON 第一三共株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284198-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON MTHFD1, MTHFD2, DHFR MTHFD2 2/4885MTHFD1 1/4885WDR5 791/4885
US-10774087-B2 Sulfonamide derivative having coumarin skeleton MTHFD1, MTHFD2, DHFR MTHFD2 2/4885MTHFD1 1/4885WDR5 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.